Vasodilator-stimulated phosphoprotein
proteinVASP phosphorylation state reflects endothelial nitric oxide signaling and serves as a marker of platelet activation resistance.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationaleNO/cGMP-dependent inhibitor of platelet activation; phosphorylation state marks anti-aggregatory signaling.
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresIndeterminate
R — rupture / Type-I—
C — confounder / Type-II33
A — assay feasibility68
E — evidence strength29
T1DI (composite)8
Specificity differential (R−C)-18
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
3hypovolemia / dehydrationn/a
4tachyarrhythmiamag 1
5hypoxemia / respiratory failuren/a
6hypertensive emergencymag 1
7high-demand / peri-operative stressn/a
Coverage: 2/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 2 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats.Arteriosclerosis, thrombosis, and vascular biology · 2006 · PMID 17023677 · doi